Musely / The Spot Pill

What it is

The Spot Pill is oral tranexamic acid, prescribed through an online consultation for melasma and post-inflammatory hyperpigmentation. It is $30 a month, starting with a three-month supply. Unlike everything else we have reviewed from this brand it is not a compounded topical — it is a systemic medicine that you swallow.

That distinction governs the whole review. A topical that is wrongly formulated wastes your money and may irritate your skin. A systemic drug given to the wrong patient is a different category of problem, and it is judged by a different standard.

The evidence is real, and the dose is right

We have spent three reviews explaining why Musely's topicals are dosed below the concentrations their trials use. It is only fair to be equally direct in the other direction: this one is dosed correctly, and the evidence behind it is the strongest in the range.

Tranexamic acid interrupts the plasminogen pathway in keratinocytes that drives UV-triggered melanogenesis. It acts upstream of tyrosinase rather than on it, which is why it works on the vascular component of melasma that survives sun exposure and why it does something hydroquinone does not.

A 2023 network meta-analysis concluded that 750 mg per day — 250 mg three times daily — for twelve consecutive weeks is the optimal dose-and-duration combination for efficacy, with 500 mg per day an acceptable alternative where adherence is a concern. Musely's page states exactly that. In one comparison, oral tranexamic acid at 250 mg twice daily alongside sunscreen and standard therapy produced 82.3% improvement against 40.8% for topical therapy alone.

The safety data is better than the mechanism suggests

Tranexamic acid is an antifibrinolytic: it inhibits the breakdown of clots. Stated that baldly it sounds alarming, and it would be easy to write a frightening paragraph here. The evidence does not support one.

No thromboembolic adverse events have been reported at the low doses used for melasma. More importantly, a recent multicentre cohort study using propensity score matching on electronic health records found that oral tranexamic acid use for melasma was not associated with thromboembolism. That is the right kind of study to answer this question and it points the reassuring way.

So the honest summary is: at melasma doses, in appropriately selected patients, this appears to be safe. Every part of that sentence is doing work, and the phrase carrying the most weight is the last one.

Everything depends on the screening

The same literature that reports the reassuring safety data is consistent about the condition attached to it: patients must be screened for contraindications and risk factors before therapy is started. The named contraindications are coagulation disorders, thromboembolic disease and severe renal insufficiency. And tranexamic acid is specifically not to be combined with hormonal contraceptives.

We want to be careful about what we are and are not claiming. We have not taken the intake questionnaire, we cannot see what a prescriber is shown, and it is entirely possible that the clinical screening behind the scenes is thorough. Musely does route this through prescribers, which is the correct architecture.

What we can assess is what is published. A page selling a systemic antifibrinolytic advertises the intake as a three-minute online visit, lists no side effects, names no contraindications, and does not mention the contraceptive interaction. Those are editorial choices about the one step the safety case depends on.

If your intake did not ask you most of these, raise them yourself before you start taking it.

One FAQ statement is not accurate

The site's FAQ states that this is not a medication related to decreasing blood loss from heavy menstrual bleeding. As a description of the drug that is incorrect. Tranexamic acid is licensed for exactly that indication — it is marketed as Lysteda for heavy menstrual bleeding, and it is used to control bleeding in haemophilia and in trauma.

We assume the intent is to say that it is not being prescribed for that purpose here, which is fair. But the sentence as written tells a reader that the drug is unrelated to haemostasis, when its haemostatic action is precisely the thing the contraindications exist to manage. A patient who reads that and concludes their clotting history is irrelevant has been misled by an FAQ that was probably trying to be reassuring.

The 90% figure, and the clock

The headline claim is that 90% of patients saw visible improvement by day 30, from 14,074 patients logging results at days 7, 30 and 60.

The structural criticism is the same as for the other three products: self-reported, uncontrolled, unblinded, assessed by the purchaser. But there is an additional problem specific to this one. The evidence base for oral tranexamic acid describes a twelve-week course, and the network meta-analysis optimum is defined over twelve weeks. Melasma is slow. A 90% response rate at day 30 sits oddly against a company that is, correctly, telling you on the same page that the course runs for twelve weeks.

A course is not a subscription

This is the third time across four reviews that we have run into the same structural issue, and it is worth naming as a pattern rather than a product fault. The Body Cream puts a high-strength depigmenting agent on a rolling subscription. The KP Cream does it with a topical steroid. The Acne Cream does it with a topical antibiotic. This one does it with a systemic drug whose evidence base is explicitly defined over twelve weeks.

Subscriptions are an excellent commercial model for consumables. Cleansers, sunscreens, moisturisers — things you use continuously and run out of. They are a poor fit for interventions the evidence describes as courses, because the default behaviour a subscription produces is continuation, and the default behaviour a course requires is a review and a decision.

If you are going to use it

• ▸Volunteer your full clotting history, family history and current medications in the intake, whether or not you are asked.
• ▸If you take a combined hormonal contraceptive, raise it explicitly and get a direct answer before you start.
• ▸Treat it as a twelve-week course with a review at the end, not an open subscription.
• ▸Wear broad-spectrum SPF daily without exception. Melasma is UV-driven and this will not hold without it.
• ▸Photograph the area monthly under fixed lighting. Melasma is gradual and memory is a poor instrument.
• ▸Stop and seek urgent medical attention for calf pain or swelling, chest pain, or breathlessness.
• ▸Do not take it if there is any chance you are pregnant.

Where we stand

Scored on the pharmacology alone this would be the clear pick of the range. The molecule has meta-analytic support, the dose matches the published optimum, the duration is stated, and the recent safety evidence is reassuring. It is a legitimate treatment for a genuinely difficult condition, sold at a fraction of the in-office price.

What keeps it at conditional rather than recommended is that this is the one product in the range where the marketing page carries a duty of care, and it is the disclosure that falls short. No side effects. No contraindications. No mention of the contraceptive interaction. An FAQ that misdescribes the drug. And a three-minute visit foregrounded as a selling point when it is the step everything else depends on.

Fixing that would cost a paragraph. It would also make this, comfortably, the best thing the company sells.